Development and evaluation of pharmacological agents targeting chemokine receptors (Q35119358)

6 August 2017

1 reference

title

Development and evaluation of pharmacological agents targeting chemokine receptors (English)

1 reference

6 August 2017

Richard Horuk

1

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12725804

29 December 2023

publication date

1 April 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S1046202302003614?httpAccept=text/xml

1 reference

10.1016/S1046-2023(02)00361-4

DOI

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

https://api.elsevier.com/content/article/PII:S1046202302003614?httpAccept=text/plain

29 December 2023

1 reference

10.1016/S1046-2023(02)00361-4

DOI

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

29 December 2023

1 reference

6 August 2017

volume

29

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

369-375

1 reference

6 August 2017

cites work

Chemokines and disease

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Chemokines: immunology's high impact factors

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Dancing to the tune of chemokines

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

1 reference

7 January 2021

Alpha(1)-adrenoceptor antagonists. 4. Pharmacophore-based design, synthesis, and biological evaluation of new imidazo-, benzimidazo-, and indoloarylpiperazine derivatives

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailabl

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Chemokine receptor antagonists

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Chemokine receptors and HIV-1: the fusion of two major research fields

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Chemokine-receptor polymorphisms: clarity or confusion for HIV-1 prognosis?

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Association of CCR5 ▵32 with reduced risk of asthma

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

CC chemokine receptor 5 and renal-transplant survival

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1016/S1046-2023(02)00361-4

7 January 2021

10.1016/S1046-2023(02)00361-4

Identifiers

DOI

1 reference

6 August 2017

1 reference